Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2021 Financial Results and Discuss Recent Corporate Highlights

Rhea-AI Summary

Aldeyra Therapeutics (NASDAQ: ALDX) announced a conference call on March 17, 2022, at 8:00 a.m. ET to discuss its financial results for the year ended December 31, 2021, along with recent corporate highlights. The call will be accessible via dial-in and a live webcast on the company’s website. Aldeyra is focused on developing therapies for immune-mediated diseases, with key candidates reproxalap in Phase 3 trials for dry eye disease and ADX-629 in Phase 2 trials for psoriasis and COVID-19. More information is available on their website.

Positive

• Aldeyra's lead product candidates, reproxalap and ADX-629, are advancing in clinical trials, indicating progress in drug development.
• The upcoming conference call will provide insights into the company's financial health and strategic direction.

Negative

• None.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, March 17, 2022 to report financial results for the year ended December 31, 2021 and discuss recent corporate highlights.

The dial-in numbers are (844) 200-6205 for domestic callers and (929) 526-1599 for international callers. The access code is 132077. A live webcast of the conference call will also be available on the Investors & Media page of the Aldeyra website at https://ir.aldeyra.com. After the live webcast, the event will remain archived on the website for 90 days.

About Aldeyra Therapeutics

Aldeyra Therapeutics discovers and develops innovative therapies designed to treat immune-mediated diseases. Our approach is to develop therapies that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 proof-of-concept clinical trials in psoriasis, asthma, and COVID-19. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220309005922/en/

Corporate:

Joshua Reed

Aldeyra Therapeutics, Inc.

Tel: 781-761-4904 ext. 218

jreed@aldeyra.com

Investors & Media:

Scott Solomon

Sharon Merrill Associates, Inc.

Tel: 617-542-5300

ALDX@investorrelations.com

Source: Aldeyra Therapeutics, Inc.

FAQ

When will Aldeyra Therapeutics announce its financial results for 2021?

Aldeyra Therapeutics will announce its financial results for the year ended December 31, 2021, on March 17, 2022.

What is the focus of Aldeyra Therapeutics' research?

Aldeyra Therapeutics focuses on developing innovative therapies for immune-mediated diseases.

What clinical trials are currently underway for Aldeyra's products?

Reproxalap is in Phase 3 trials for dry eye disease, while ADX-629 is in Phase 2 trials for psoriasis and COVID-19.